Tharimmune announces positive results in phase 1 clinical trial of th104, its lead clinical therapeutic candidate

Positive safety/tolerability profile achieved with th104 showing self-resolving, mild side effect profile aligned with previous studies phase 1 clinical trial compared oral transmucosal delivery of th104 to injectable reference approved drug completed company fully funded into 2025 with phase 2 moderate-to-severe chronic pruritus in primary biliary cholangitis (pbc) study on-track and expected to initiate in 2024 bridgewater, nj / accesswire / february 20, 2024 / tharimmune, inc. (nasdaq:thar) ("tharimmune" or the "company"), a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology announced today the completion of the company's phase 1 clinical trial with th104. th104 is a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene which easily adheres inside of the mouth on the cheek and biodegrades within minutes.
THAR Ratings Summary
THAR Quant Ranking